Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Clinical trial of creatine in amyotrophic lateral sclerosis [ALS] Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Clinical trial of creatine in amyotrophic lateral sclerosis [ALS] conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Clinical trial of creatine in amyotrophic lateral sclerosis [ALS] Clinical research trials and Clinical trial of creatine in amyotrophic lateral sclerosis [ALS] healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Clinical trial of creatine in amyotrophic lateral sclerosis [ALS]. Clinical trial of creatine in amyotrophic lateral sclerosis [ALS] Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Clinical trial of creatine in amyotrophic lateral sclerosis [ALS] clinical trial. Human subjects often obtain the finest healthcare possible for their Clinical trial of creatine in amyotrophic lateral sclerosis [ALS] condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.

Home > "C" Clinical Trials Conditions > Clinical trial of creatine in amyotrophic lateral sclerosis [ALS]

Clinical trial of creatine in amyotrophic lateral sclerosis [ALS]



Clinical trial of creatine in amyotrophic lateral sclerosis [ALS]

For Condition: Amyotrophic Lateral Sclerosis
Status: Completed
Sponsor(s): National Center for Research Resources (NCRR) , Muscular Dystrophy Association
Synopsis: The purpose of this study is to evaluate the safety and effectiveness of creatine treatment in amyotrophic lateral sclerosis (ALS). There is currently no known effective treatment for ALS. It is known that nerve cells die in the brains and spinal cords of patients with ALS but the cause of the cell death is unknown. It has been shown that there is overactive nerve activity due to increased levels of a chemical called glutamate and that there is abnormal cellular metabolism along with increased production of substance called "free radicals." Improving cellular metabolism and readjusting the activity of glutamate in the brain may be beneficial to ALS patients. Creatine is a naturally occurring compound, which improves energy metabolism in cells. Creatine has been given to patients with energy metabolism defects in their muscles, and to athletes. Creatine improves survival in a mouse model of ALS. Three human subjects with ALS have received creatine for up to six months without any side effects. Overall, creatine has been well tolerated and safe.
Details: Half of the subjects in this study will be selected by chance to receive creatine treatment for 6 months and the other half to receive placebo. Neither the subject nor the investigator will know which drug the subject is receiving, although this information will be available in case of emergency. It is anticipated that all subjects will have the choice to receive creatine after the 6 months study in an open-label study for an additional 12 months. A total of 114 patients will participate at 15 centers. Approximately 8 subjects will be enrolled at the Washington University. The effectiveness of creatine will be determined first by assessing any changes in strength in the arms and second by changes in grip strength, functional activities, electromyography changes or changes of the level of SOH 2'dG in the urine.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/80 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - A clinical diagnosis of definite, probably or laboratory supported probably ALS, either sporadic or familial ALS according to a modified El Escorial criteria - Willing and able to give informed consent - FVC greater than or equal to 50% predicted - Evidence of abnormality in upper and/or lower extremity motor function (clinical evidence of muscle atrophy and weakness in an upper and/or lower extremity). The patient should have at least 4 or 8 testable upper extremity muscle groups. - Subjects may take riluzole. Riluzole must have been at stable doses for at least thirty days prior to baseline visit. - If woman of childbearing age, must be non-lactating and surgically sterile or using an effective method of birth control (double barrier or oral contraceptive) and have a negative pregnancy test - Disease duration less than five years
Total Enrollment: 

Location and Contact Information:

Washington University
St. Louis,  Missouri,  63110
United States
 


Additional Information:
Study ID Numbers:  NCRR-M01RR00036-0745;  M01RR00036
Study Start Date: 
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005674

Other Amyotrophic Lateral Sclerosis Studies:
1. Exogenous Toxicants and Genetic Susceptibility in ALS

2. Phase II Study of Leuprolide and Testosterone for Men with Kennedy's Disease or Other Motor Neuron Disease

3. Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS

4. Safety testing of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Laughter & Crying)

5. Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis

Related Studies:

Other Amyotrophic Lateral Sclerosis Clinical Trials
Other Missouri Clinical Trials
Other St. Louis Clinical Trials

Clinical trial of creatine in amyotrophic lateral sclerosis [ALS]
Modify your Search

  Other Amyotrophic Lateral Sclerosis Clinical Trials
  Other Missouri Clinical Trials
  Other St. Louis Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103